Survival Analysis: a branch of statistics for analyzing the expected duration of time until one or more events happen, such as death in biological organisms and failure in mechanical systems.
-
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
MAY 31, 2023 | 10:00 AM
C.E. CREDITS
Date: May 31, 2023 Time: 10:00am (PDT), 1:00pm (EDT), 5:00pm (CEST) Bloodstream infections (BSIs) are defined as a systemic infection resulting from the presence of viable microorganisms in...
Date: September 15, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Tyrosine kinases, a ubiquitous and diverse family of enzymes, are of considerable clinical interest because they dir...
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
Date: October 28, 2020 Time: 7:00am (PDT), 10:00am (EDT) Although chemotherapy remains the mainstay of systemic therapy, a large number of cancer patients fail to respond to it. About half o...
Individuals of under-represented minority ancestry are at disproportional risk for higher incidence and mortality rates for particular cancers. The unequal burden of cancer in certain racial...
Background: Healthcare access (HCA) encompasses five important dimensions: Affordability, Availability, Accessibility, Accommodation and Acceptability. Published studies of cancer typically...
Chronic kidney disease (CKD) is a major public health threat, affecting 11-15% of the U.S. population alone. Currently, there are no effective therapies to cure CKD. Drug therapies are not p...
Chronic kidney disease (CKD) is a global health threat, affecting over 10% of the world population, including an estimated 37 million Americans. Importantly, glomerular diseases account for...
DATE: September 1, 2020 TIME: 8:00am PT, 11:00am ET Nearly half of all cancer patients are eligible to receive treatment with immune checkpoint inhibitors (ICI). Thus, preventing, identifyin...
B7-H3 is actively being explored as an immunotherapy target for pediatric patients with solid tumors using monoclonal antibodies or T cells expressing chimeric antigen receptors (CARs). B7-H...